Vericel (VCEL) Non Operating Income (2010 - 2026)
Vericel (VCEL) posted Non Operating Income of $1.8 million for Q2 2026, up 0.57% sequentially from $1.8 million in Q1 2026, and up 20.05% YoY from $1.5 million in Q2 2025.
Analysis
Vericel (VCEL) Non Operating Income (2010 - 2026) Analysis & Trends
Vericel has reported Non Operating Income for 17 years, with the latest figure at $1.8 million in Q2 2026.
- Quarterly Non Operating Income rose 20.05% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.8 million (up 12.92% YoY) and the FY2025 annual result came in at $6.3 million, up 5.71% from the prior year.
- Non Operating Income grew to $1.8 million in Q2 2026 per VCEL's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non Operating Income peaked at $1.8 million in Q2 2026 and troughed at $119000.0 in Q2 2022.
- A 5-year average of $1.2 million and a median of $1.4 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 693.33% in 2022, then retreated 3.5% in 2025.
- Over 5 years, Non Operating Income stood at $537000.0 in 2022, then jumped by 153.63% to $1.4 million in 2023, then increased by 8.37% to $1.5 million in 2024, then gained by 14.3% to $1.7 million in 2025, then grew by 5.04% to $1.8 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.8 million, $1.8 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 1.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Mn |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 1.69 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 941,000.00 |
| Mar 31, 2023 | 682,000.00 |
| Dec 31, 2022 | 537,000.00 |
| Sep 30, 2022 | 232,000.00 |
| Jun 30, 2022 | 119,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | 30,000.00 |